TYK2 and psoriasis vulgaris: The findings reported here provide additional support that deucravacitinib, a once‐daily oral TYK2 inhibitor, is an efficacious and well‐tolerated therapeutic option for Japanese patients with moderate to severe plaque psoriasis.